close

Agreements

Date: 2017-06-13

Type of information: Nomination

Compound:

Company: Ablynx (Belgium)

Therapeutic area:

Type agreement: nomination

Action mechanism:

Disease:

Details:

  • • On June 13, 2017, Ablynx announced the appointment of Markus L.E. Ewert as Chief Business Officer (CBO). Effective from 20 June 2017, Dr Ewert will lead business development and corporate strategy activities and become a member of the Executive Committee. Dr Ewert has worked for nearly 30 years in the life sciences industry and has held a number of senior business and commercial positions.
  • Until recently, Dr Ewert headed the Business Development team of the Healthcare division of General Electric and in that capacity executed numerous deals. Prior to that, he worked at Novartis in its Cardiovascular and Metabolism franchise and later moved to the Molecular Diagnostics unit as Head of Strategy, Global BD&L, and M&A. Before joining Novartis, Dr Ewert was CEO of two biotech companies and had been at The Boston Consulting Group serving as an advisor to pharmaceutical and chemical companies. Dr Ewert holds a PhD in molecular biology from the University of Heidelberg and an MBA from the University of Chicago.

Financial terms:

Latest news:

Is general: Yes